Home > Haematology > EHA 2021 > Lymphoma > MATRix with ASCT: best long-term survival for primary CNS lymphoma

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By
Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany
Conference
EHA 2021
Trial
Phase 2, IELSG32
At 7 years of follow-up, MATRix treatment with whole-brain irradiation or autologous stem cell transplantation (ASCT) consolidation showed excellent long-lasting survival in patients with primary central nervous system (CNS) lymphoma in the randomised, phase 2 IELSG32 trial. Primary CNS lymphoma is an aggressive lymphoma in a special, immune-privileged, and highly sensitive environment. The open-label, randomised, phase 2 IELSG32 trial (NCT01011920) has shown significantly increased efficacy and acceptable safety of the MATRix regimen (i.e. rituximab ± thiotepa plus methotrexate and cytarabine), and comparable efficacy of consolidation with whole-brain irradiation therapy (WBRT) or ASCT in patients ≤70 years of age [1,2]. Dr Gerald Illerhaus (Klinikum der Landeshauptstadt Stuttgart, Germany) presented the updated results at a med...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on